Diabetes Alert: Insulin Syringes Recalled

Company Recalls 471,000 ReliOn Insulin Syringes Because of Possible Mislabeling and Overdose Risk

Tyco Healthcare Group LP (Covidien), has recalled one lot of ReliOn sterile, single-use hypodermic syringes sold at Wal-Mart and Sam's Clubs stores. The syringes were recalled because of the potential that they are mislabeled and potentially contain more than twice the intended dose. Patients are advised of the serious health risks associated with receiving the high dose including, hypoglycemia and death. One incident has been reported, according to the Food and Drug Administration.

"The use of these syringes may lead to patients receiving an overdose of as much as 2.5 times the intended dose, which may lead to hypoglycemia, serious health consequences, and even death," according to an FDA news release.

The recall only applies to the following products:

  • Product name: ReliOn Insulin Syringes - 31 gauge 1 cc (100 syringes per box)
  • Lot number: 813900 (on the back panel of the carton, or on the white paper backing of each syringe's "peel pack")
  • Product identification number: 38396-0403-02 (on the top panel upper right-hand corner of the syringe box)

The FDA says some syringes labeled for use with U-40 insulin got packaged with syringes for U-100 insulin. The FDA notes that Tyco Healthcare recalled this lot of syringes in October, and Wal-Mart and Sam's Club stores have posted information about the recall and notified more than 16,500 customers about the recall.

If you are interested in referring cases or associating with us on these cases, please contact one of our attorneys: Kristian Rasmussen, or Jerome Tapley, or phone (800) 852-6299. We look forward to hearing from you.



Refer a Colleague
If you have a colleague who would benefit from receiving the eBulletin, contact Dawn Bowman at dbowman@cwcd.com.



Update Your Contact Information
You may change your email address, update your contact information or unsubscribe from the eBulletin at any time by contacting Dawn Bowman at dbowman@cwcd.com.


 

 

Home | Firm Profile | News | In the Community | FAQ | Resources | Contact

 
 

Having trouble viewing this e-mail? Click here to view it on the Web.
If you would like to unsubscribe from this email, please click here: unsubscribe.